Translational Research Laboratory for Urological Diseases, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Comprehensive Genitourinary Cancer Center, the First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, P. R. China.
Cell Death Dis. 2024 Nov 19;15(11):844. doi: 10.1038/s41419-024-07245-w.
The RON receptor tyrosine kinase is critical in the pathogenesis of various cancer types, however, its role in bladder cancer invasive growth is still largely unknown. Here, we found that over 90% of bladder cancer samples exhibit elevated levels of RON expression, with significantly higher expression levels observed in invasive bladder cancer compared to non-invasive bladder cancer. In vitro, RON activation resulted in increased bladder cancer cell migration and invasiveness. Results from mRNA sequencing and transcriptome analysis further demonstrated that MMP12, a downstream molecule of RON, is functionally involved in regulating RON-mediated bladder cancer cell migration and invasiveness. The underlying mechanism appeared to be the RON-mediated inhibition of HIF-2α ubiquitination, which is channeled through the activation of the JNK signaling pathway. Consequently, the activated JNK pathway increased MMP12 expression, ultimately driving bladder cancer cell migration and invasion. As evident in bioinformatics and dual-luciferase reporter assays, the RON mRNA at its 3'-untranslated regions specifically interacted with hsa-miR-659-3p. The binding of hsa-miR-659-3p downregulated the RON gene expression, attenuating the receptor-mediated tumorigenic activities of bladder cancer cells in vitro and in vivo. In conclusion, aberrant RON expression in bladder cancer cells and MMP12 and HIF-2α activities form a functional axis that causes increased bladder cancer cell migration and invasion. The fact that hsa-miR-659-3p downregulates RON expression indicates its critical role in attenuating RON-mediated tumorigenic effect on bladder cancer cells. These findings highlight the importance of RON targeting as a therapeutic means for potential bladder cancer therapy.
RON 受体酪氨酸激酶在多种癌症类型的发病机制中起着关键作用,然而,其在膀胱癌侵袭性生长中的作用在很大程度上仍不清楚。在这里,我们发现超过 90%的膀胱癌样本表现出 RON 表达水平升高,侵袭性膀胱癌的表达水平明显高于非侵袭性膀胱癌。在体外,RON 激活导致膀胱癌细胞迁移和侵袭性增加。mRNA 测序和转录组分析的结果进一步表明,RON 的下游分子 MMP12 参与调节 RON 介导的膀胱癌细胞迁移和侵袭。潜在的机制似乎是 RON 介导的 HIF-2α 泛素化抑制,这是通过 JNK 信号通路的激活来实现的。因此,激活的 JNK 途径增加了 MMP12 的表达,最终驱动膀胱癌细胞的迁移和侵袭。正如生物信息学和双荧光素酶报告基因检测所表明的那样,RON mRNA 在其 3'-非翻译区特异性地与 hsa-miR-659-3p 相互作用。hsa-miR-659-3p 的结合下调了 RON 基因的表达,减弱了 RON 受体在体外和体内介导的膀胱癌细胞的致瘤活性。总之,膀胱癌细胞中异常的 RON 表达和 MMP12 和 HIF-2α 的活性形成了一个功能轴,导致膀胱癌细胞迁移和侵袭增加。hsa-miR-659-3p 下调 RON 表达表明其在减弱 RON 介导的膀胱癌细胞致瘤作用方面具有重要作用。这些发现强调了 RON 靶向作为潜在膀胱癌治疗的治疗手段的重要性。